Clinical Guideline Development Groups
Multidisciplinary groups developing clinical practice guidelines and treatment protocols for psychedelic-assisted therapy.
All Organisations
American Psychiatric Association
US professional psychiatric body that publishes position statements and guidance relevant to evidence standards and clinical policy considerations for psychedelic and empathogenic therapies.
Colorado Natural Medicine Advisory Board
Statutorily created Colorado advisory board providing implementation recommendations for natural medicine regulation, safety standards, licensing architecture, and program oversight priorities.
European Medicines Agency (EMA)
EU medicines regulator coordinating scientific and policy dialogue on psychedelic medicinal products, including multi-stakeholder work toward regulatory framework design in the European context.
Oregon Psilocybin Advisory Board
State advisory board charged with issuing recommendations to Oregon Health Authority on psilocybin services implementation, professional standards, public health safeguards, and operational controls.
Royal Australian and New Zealand College of Psychiatrists (RANZCP)
Regional psychiatric college issuing clinical memoranda and implementation guidance on psychedelic-assisted therapy, including MDMA and psilocybin use in regulated psychiatric contexts.